Patient No. | HIV1/2 anti-body | Genotypes at 8 loci | |||||||
---|---|---|---|---|---|---|---|---|---|
ITS | mtLSU rRNA | β-Tub | 26S rRNA | ||||||
SX_0001 | +/− | ITS2 + ITS59 | mt3 | β-Tub1 + β-Tub2 | 26S2 | ||||
SX_0002 | +/− | ITS4 | mt3 | β-Tub2 | 26S2 | ||||
SX_0003 | −/− | ITS10 + ITS16 | mt1 + mt 2 | β-Tub1 + β-Tub2 | 26S3 + 26S4 |
Locus | Genotypes |
Location |
No. of plasmid clones sequenced | ||
---|---|---|---|---|---|
SX_0001 | SX_0002 | SX_0003 | |||
ITS | ITS 4 | KC470776 | 0 | 12 | 0 |
ITS 10 | JQ365725 | 0 | 0 | 4 | |
ITS 16 | AB469817 | 0 | 0 | 8 | |
ITS 22 | KC470795 | 6 | 0 | 0 | |
ITS 59 | MK300661 | 10 | 0 | 0 | |
110C/215T | 11 | 13 | 8 | ||
110T/215C | 0 | 0 | 2 | ||
165A (55Thr) / 171C (57Pro) | 12 | 12 | 12 | ||
312C (117Gly) | 12 | 11 | 11 | ||
279C/348A/516C/547C/566C/838C | 0 | 0 | 6 | ||
279C/348A/516C/547C/566C/838T | 0 | 8 | 0 | ||
279C/348A/516C/547C/566T/838C | 9 | 0 | 0 | ||
279T/348A/516C/547C/566C/838C | 0 | 0 | 3 | ||
mt LSU rRNA | mt1 | 85C/248C | 0 | 0 | 2 |
mt2 | 85A/248C | 0 | 0 | 8 | |
mt3 | 85T/248C | 10 | 10 | 0 | |
β-Tub | β-Tub 1 | 86G/281A | 8 | 0 | 6 |
β-Tub 2 | 86G/281G | 4 | 12 | 5 | |
26S rRNA | 26S 2 | 86T/290A | 12 | 11 | 0 |
26S 3 | 86C/290A | 0 | 0 | 5 | |
26S 4 | 86A/290A | 0 | 0 | 6 |
MLST types |
β-Tub | 26S rRNA | Patient no. | ||
---|---|---|---|---|---|
3 | 1 | 1 | 4 | 2 | SX_0003 |
8 | 2 | 8 | 4 | 1 | SX_0003 |
13 | 1 | 1 | 4 | 1 | SX_0003 |
15 | 1 | 8 | 4 | 1 | SX_0003 |
19 | 1 | 8 | 3 | 2 | SX_0003 |
21 | 2 | 1 | 3 | 1 | SX_0003 |
22 | 2 | 1 | 3 | 2 | SX_0003 |
23 | 2 | 1 | 4 | 1 | SX_0003 |
35 | 2 | 7 | 2 | 1 | SX_0001 |
51 | 1 | 7 | 2 | 1 | SX_0001 |
52 | 2 | 2 | 2 | 1 | SX_0002 |
NA | 1 | 1 | 3 | 2 | SX_0003 |
NA | 2 | 8 | 3 | 1 | SX_0003 |
NA | 2 | 8 | 3 | 2 | SX_0003 |
NA | 2 | 1 | 4 | 2 | SX_0003 |
NA | 2 | 8 | 4 | 2 | SX_0003 |
NA | 1 | 1 | 3 | 1 | SX_0003 |
NA | 1 | 8 | 3 | 1 | SX_0003 |
NA | 1 | 8 | 4 | 2 | SX_0003 |
Genes (reference) | Primer names and sequences (5′-3′) | Size of nested PCR products (bp) |
---|---|---|
ITS ( |
1724F 5′-AAGTTGATCAAATTTGGTC-3′ |
578 |
MnSOD_Fw 5′-GGGTTTAATTAGTCTTTTTAGGCAC-3′ |
560 | |
FR208 5′-GCAGAAAGTAGGTACATTATTACGAGA-3′ |
798 | |
DHPS1 5′-CAAATTAGCGTATCGAATGACC-3′ |
278 | |
CytbFw 5′-CCCAGAATTCTCGTTTGGTCTATT-3′ |
590 | |
mtLSU rRNA ( |
pAZ102_E 5′-GATGGCTGTTTCCAAGCCCA-3′ |
252 |
β-Tub ( |
Pneumo |
303 |
26S rRNA ( |
PneumoLSU_F 5′-TCAGGTCGAACTGGTGTACG-3′ |
297 |
Clinical information | Patient No. | ||
---|---|---|---|
SX_0001 | SX_0002 | SX_0003 | |
Age (years) | 65 | 51 | 65 |
Sex | Male | Male | Male |
Underlying conditions | NA |
Hepatic cysts | ILD |
Thoracic HRCT findings | GGO d + | GGO + | GGO + |
HIV 1/2 antibody | +/– | +/– | –/– |
CD4 T-lymphocyte count (cells/µl) | 232 | 176 | NA |
Serum parameters | |||
1,3-β-D-glucan, normal < 10 pg/ml | > 600 | NA | > 600 |
Lactate dehydrogenase, normal 120–250 U/l | 432 | 699 | 9,734 |
C-reactive protein, normal 0–6 mg/l | 73.63 | 129.17 | 340.00 |
Procalcitonin, normal 0–0.05 ng/ml | 0.975 | 0.161 | 11.26 |
Partial pressure of oxygen, normal 80–110 mmHg | 80 | 65 | 59.70 |
Erythrocyte sedimentation rate, normal 0–15 mm/h | 61.10 | 60.80 | 47.30 |
Concurrent infection | – | – | |
Anti-PCP therapy |
– | – | – |
HAART before PCP | – | – | – |
Clinical outcomes | survived | survived | died |